Tvardi Therapeutics (NASDAQ:TVRD) Upgraded at Lucid Cap Mkts

Lucid Cap Mkts upgraded shares of Tvardi Therapeutics (NASDAQ:TVRD) from a hold rating to a strong-buy rating in a report published on Wednesday,Zacks.com reports.

TVRD has been the topic of a number of other research reports. Cantor Fitzgerald lowered shares of Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 13th. BTIG Research decreased their price target on shares of Tvardi Therapeutics from $55.00 to $15.00 and set a “buy” rating on the stock in a research report on Monday, October 13th. Wall Street Zen lowered shares of Tvardi Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 23rd. Weiss Ratings reiterated a “sell (e)” rating on shares of Tvardi Therapeutics in a research note on Monday, December 29th. Finally, Piper Sandler lowered Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, October 13th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $55.50.

Tvardi Therapeutics Stock Performance

NASDAQ TVRD opened at $3.72 on Wednesday. The stock has a 50-day simple moving average of $4.20 and a 200 day simple moving average of $15.37. Tvardi Therapeutics has a twelve month low of $3.50 and a twelve month high of $43.65. The stock has a market capitalization of $34.89 million, a PE ratio of -0.39 and a beta of 0.14.

Tvardi Therapeutics (NASDAQ:TVRD) last released its earnings results on Thursday, November 13th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.24.

Institutional Investors Weigh In On Tvardi Therapeutics

A number of institutional investors have recently added to or reduced their stakes in TVRD. JPMorgan Chase & Co. acquired a new position in shares of Tvardi Therapeutics in the 2nd quarter worth approximately $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Tvardi Therapeutics in the second quarter valued at $43,000. Headlands Technologies LLC bought a new stake in Tvardi Therapeutics in the second quarter valued at $80,000. New York State Common Retirement Fund acquired a new position in Tvardi Therapeutics during the second quarter worth $92,000. Finally, Squarepoint Ops LLC bought a new position in shares of Tvardi Therapeutics during the third quarter valued at $318,000. 44.66% of the stock is owned by institutional investors and hedge funds.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.